HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

IFF third quarter

This article was originally published in The Rose Sheet

Executive Summary

Fueled by growth in North America and Europe, worldwide fragrance sales increased 5% in dollars during the third quarter on pro forma basis, fragrance and flavor supplier announces in 1Oct. 24 release. North American fragrance sales grew 2%, as fine perfumery and aromachemicals each increased in "high single-digits." European fragrance sales up 8% in local currency, with 25% local currency fine fragrances gain based on new wins and pick-up in travel retail. Global flavor sales rose 5% in the quarter, contributing to 5% consolidated sales increase to $462.8 mil. versus comparable 2001 results. Net income up 18% to $49.6 mil., excluding nonrecurring charges. Integration of Bush Boake Allen completed during the quarter, IFF announces, providing savings "run rate" of $80 mil., ahead of plan. Firm projects Q4 consolidated dollar sales to increase in low single-digits, earnings per share to rise 8%-12%, excluding charges...

You may also be interested in...



QUOTED. 19 February 2020. Stephen Hahn.

The US FDA has abandoned all near-term plans to inspect Chinese manufacturing facilities in the wake of the coronavirus crisis. See what agency head Stephen Hahn said about it here.

DevaCurl Faces Multiple Class Actions As Latest Brand Linked To Hair Loss

The company maintains that its products are safe, but plaintiffs in proposed class actions allege it has knowingly put consumers at risk of hair loss and other injuries. DevaCurl’s troubles escalated quickly after a former brand ambassador went viral with a 31 January video urging consumers to stop using DevaCurl products and adopt safer alternatives.

Could ICER Outreach To US FDA Lead To Better Cost Effectiveness Analyses?

To aid its value assessments, ICER is interested in helping FDA understand the importance of patient-relevant outcomes and consistent endpoints across trials of drugs for the same disease.

UsernamePublicRestriction

Register

RS010703

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel